<DOC>
	<DOCNO>NCT02678260</DOCNO>
	<brief_summary>The purpose study characterize safety , tolerability , Pharmacokinetics ( PK ) , antitumor activity PDR001 administer intravenous ( i.v . ) single agent Japanese patient .</brief_summary>
	<brief_title>Phase I Study PDR001 Patients With Advanced Malignancies .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients advanced/metastatic solid tumor , measurable nonmeasurable disease determine response evaluation criterion solid tumor ( RECIST ) version 1.1 , progress despite standard therapy intolerant standard therapy , standard therapy exist ECOG Performance Status â‰¤ 2 Active autoimmune disease Active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection Prior PD1 PDL1directed therapy Other protocol define inclusion/exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Advanced malignancy</keyword>
	<keyword>PDR001</keyword>
	<keyword>Japanese patient</keyword>
	<keyword>adult</keyword>
</DOC>